| Name | Title | Contact Details |
|---|
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company`s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age. Endologix is currently marketing the AFX® Endovascular AAA System is available in the U.S., Europe, Latin America and other regions. The Nellix® EndoVascular Aneurysm Sealing System, a novel aneurysm sealing system, is approved for sale in Europe and other markets and for investigational use in the U.S. The Powerlink with IntuiTrak® Delivery System is available in Japan. These technologies are minimally invasive, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Endologix products are protected by at least 52 U.S. patents with at least 956 allowed claims. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company`s corporate office is located in Irvine, California.
Founded in 2006, Ocular Therapeutix is a fast-growing, aspiring leader in the biopharmaceutical industry. The company has a clear vision – to improve current therapeutic options in ophthalmology by encapsulating previously approved therapeutic agents in our novel hydrogel to provide a sustained delivery of drugs to the eye. We are reframing the industry with new modalities for ophthalmic therapies. As a small company, our employees are provided the unique opportunity to help build the foundation of the business as it grows. We strongly believe that our success is contingent upon the achievements of our employees. We strive to create a collaborative, challenging environment that encourages individuals to bring success to their career and the company. Through the use of our proprietary hydrogel technology, we strive to offer superior products that improve the world’s vision.
Medacta International is a Swiss company developing, manufacturing and distributing orthopaedic and neurosurgical medical devices worldwide. Founded in 1999 with a vision to create a better patient experience for people needing joint and spine treatment, Medacta specializes in highly innovative minimally-invasive, personalized approaches designed to bring renewed hope and optimism to patients. Medacta is a recognized leader in Hip Replacement with its proprietary AMIS® (Anterior Minimally Invasive Surgery) product offerings and in Knee Replacement via MyKnee® Patient Matched 3-D printing technology. At the 2014 North American Spine Society (NASS) Annual Meeting, Medacta`s new MySpine® Patient Matched product was awarded "Best New Technology - Posterior Thoracolumbar Spine Treatments".
Obbligato Objectives is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
OrthoGrid Systems is a rapidly expanding global leader in orthopedic imaging technology with specialized applications available or in development for hip arthroplasty, trauma, knee replacement, and other common procedures performed over 1 million times per year in aggregate in the USA and 3 million times globally. OrthoGrid helps to overcome the limitations of traditional low resolution, distorted imaging technology by providing computerized image correction and image guidance direction to physicians performing orthopedic procedures.